NO20054398L - 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose - Google Patents

4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Info

Publication number
NO20054398L
NO20054398L NO20054398A NO20054398A NO20054398L NO 20054398 L NO20054398 L NO 20054398L NO 20054398 A NO20054398 A NO 20054398A NO 20054398 A NO20054398 A NO 20054398A NO 20054398 L NO20054398 L NO 20054398L
Authority
NO
Norway
Prior art keywords
treatment
acid derivatives
ylmethoxy
oxazol
cyclohexyloxy
Prior art date
Application number
NO20054398A
Other languages
English (en)
Other versions
NO20054398D0 (no
Inventor
Heiner Glombik
Eugen Falk
Hans-Ludwig Schaefer
Stefanie Keil
Dirk Gretzke
Christian Stapper
Jochen Goerlitzer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054398D0 publication Critical patent/NO20054398D0/no
Publication of NO20054398L publication Critical patent/NO20054398L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Det beskrives arylcykloalkylsubstituerte alkansyrederivater, samt deres fysiologisk kompatible salter og fysiologisk funksjonelle derivater. Foreliggende oppfinnelse angår forbindelser med formel I hvor restene har den ovenfor angitte betydning, såvel som deres fysiologisk godtagbare salter og fremgangsmåte til deres fremstilling. Spesielt egnet er slike forbindelser for behandling og/eller prevensjon av forstyrrelser av fettsyrestoffskifte og glukoseutnyttelsesforstyrrelser, så vel som forstyrrelser der insulinresistens spiller en rolle.
NO20054398A 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose NO20054398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (2)

Publication Number Publication Date
NO20054398D0 NO20054398D0 (no) 2005-09-22
NO20054398L true NO20054398L (no) 2005-11-02

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054398A NO20054398L (no) 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose

Country Status (34)

Country Link
US (5) US7259177B2 (no)
EP (3) EP1599453B1 (no)
JP (3) JP2006519194A (no)
KR (3) KR20050106461A (no)
CN (3) CN100439347C (no)
AR (3) AR043427A1 (no)
AT (3) ATE435217T1 (no)
AU (3) AU2004215673B2 (no)
BR (3) BRPI0407814A (no)
CA (3) CA2516620A1 (no)
CL (2) CL2004000391A1 (no)
CO (2) CO5690578A2 (no)
DE (4) DE10308355A1 (no)
DK (3) DK1599455T3 (no)
EC (2) ECSP055986A (no)
ES (3) ES2287700T3 (no)
HR (3) HRP20050742A2 (no)
IL (2) IL170316A (no)
MA (3) MA27737A1 (no)
MX (3) MXPA05008988A (no)
NO (3) NO20054398L (no)
OA (2) OA13034A (no)
PA (1) PA8596801A1 (no)
PE (3) PE20050292A1 (no)
PL (3) PL377735A1 (no)
PT (3) PT1599453E (no)
RS (1) RS20050594A (no)
RU (3) RU2005129995A (no)
SA (1) SA04250153A (no)
TN (2) TNSN05204A1 (no)
TW (3) TW200500349A (no)
UY (2) UY28210A1 (no)
WO (3) WO2004076428A1 (no)
ZA (2) ZA200505765B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
WO2008018138A1 (en) 2006-08-10 2008-02-14 Wood One Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
WO2009021987A1 (en) 2007-08-16 2009-02-19 Solvay (Société Anonyme) Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
NZ587261A (en) 2008-02-29 2012-05-25 Nissan Chemical Ind Ltd Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
EP3726298B1 (en) 2017-12-13 2022-10-26 Canon Kabushiki Kaisha Cartridge and image forming device {}
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO1999046232A1 (en) * 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (en) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
IL148148A0 (en) 1999-09-01 2002-09-12 Aventis Pharma Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
WO2001040171A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
EP1277745A4 (en) 2000-04-25 2004-09-15 Kyorin Seiyaku Kk NEW STABLE CRYSTALS OF THIAZOLIDINDION DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US6861444B2 (en) 2000-04-28 2005-03-01 Asahi Kasei Pharma Corporation Bicyclic compounds
MXPA02010452A (es) 2000-05-11 2003-06-06 Bristol Myers Squibb Co Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento.
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
MXPA02011458A (es) 2000-06-09 2003-04-25 Aventis Pharma Gmbh Derivados de acilfenilurea, metodos para su produccion y uso de los mismos como farmacos.
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
BR0113409A (pt) * 2000-08-23 2003-07-01 Lilly Co Eli Agonistas de receptores ativados por proliferadores de peroxissomas
ATE368653T1 (de) 2000-08-23 2007-08-15 Lilly Co Eli Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU1609702A (en) 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
ES2291378T3 (es) * 2000-12-25 2008-03-01 Ono Pharmaceutical Co., Ltd. Compuestos derivados de dihidronaftaleno y medicamentos que utilizan estos compuestos como ingrediente activo.
CA2438551A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
EE05418B1 (et) 2001-08-31 2011-06-15 Aventis Pharma Deutschland Gmbh Diarltskloalklderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
WO2004076426A1 (de) 2004-09-10
IL170314A (en) 2010-11-30
ECSP055985A (es) 2006-01-16
UY28209A1 (es) 2004-09-30
US7259177B2 (en) 2007-08-21
CN1753879A (zh) 2006-03-29
CL2004000392A1 (es) 2005-04-22
NO20054396L (no) 2005-11-11
MA27737A1 (fr) 2006-02-01
PE20050293A1 (es) 2005-05-24
US7335671B2 (en) 2008-02-26
JP2006519199A (ja) 2006-08-24
NO20054396D0 (no) 2005-09-22
CN100439345C (zh) 2008-12-03
TW200500349A (en) 2005-01-01
DK1599453T3 (da) 2009-08-24
PE20040959A1 (es) 2005-01-17
US7365084B2 (en) 2008-04-29
DE10308355A1 (de) 2004-12-23
BRPI0407814A (pt) 2006-02-14
CA2516620A1 (en) 2004-09-10
CO5690580A2 (es) 2006-10-31
TW200510352A (en) 2005-03-16
RU2005130002A (ru) 2006-01-27
SA04250153A (ar) 2005-12-03
MXPA05008951A (es) 2005-11-04
CN100439347C (zh) 2008-12-03
CA2517381A1 (en) 2004-09-10
AU2004215672B2 (en) 2010-01-07
MA27736A1 (fr) 2006-02-01
US20050101637A1 (en) 2005-05-12
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
WO2004076427A1 (de) 2004-09-10
MA27742A1 (fr) 2006-02-01
PT1599452E (pt) 2007-09-12
EP1599453A1 (de) 2005-11-30
BRPI0407907A (pt) 2006-02-14
KR20050106461A (ko) 2005-11-09
AR043433A1 (es) 2005-07-27
WO2004076428A1 (de) 2004-09-10
TW200508210A (en) 2005-03-01
AU2004215672A1 (en) 2004-09-10
UY28210A1 (es) 2004-09-30
AU2004215673B2 (en) 2009-10-01
ES2287700T3 (es) 2007-12-16
CN1756748A (zh) 2006-04-05
CN1753881A (zh) 2006-03-29
PT1599455E (pt) 2009-09-29
AR043427A1 (es) 2005-07-27
DK1599455T3 (da) 2009-11-09
EP1599452B1 (de) 2007-06-20
PT1599453E (pt) 2009-07-14
OA13035A (en) 2006-11-10
ATE365159T1 (de) 2007-07-15
DE502004004139D1 (de) 2007-08-02
DE502004009453D1 (de) 2009-06-18
AU2004215677A1 (en) 2004-09-10
JP2006519193A (ja) 2006-08-24
HRP20050742A2 (en) 2006-09-30
ZA200505768B (en) 2005-11-23
RU2005129992A (ru) 2006-02-10
KR20050105492A (ko) 2005-11-04
RS20050594A (sr) 2007-12-31
US20050215596A1 (en) 2005-09-29
ES2329366T3 (es) 2009-11-25
US7872034B2 (en) 2011-01-18
DE502004009690D1 (de) 2009-08-13
PE20050292A1 (es) 2005-05-24
NO20054408D0 (no) 2005-09-22
PL378437A1 (pl) 2006-04-03
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
ATE435217T1 (de) 2009-07-15
CN100398526C (zh) 2008-07-02
PL378130A1 (pl) 2006-03-06
TNSN05204A1 (en) 2007-06-11
HRP20050744A2 (en) 2006-09-30
EP1599453B1 (de) 2009-05-06
CL2004000391A1 (es) 2005-01-07
CA2517386A1 (en) 2004-09-10
NO20054398D0 (no) 2005-09-22
TNSN05206A1 (en) 2007-06-11
ZA200505765B (en) 2006-05-31
AU2004215673A1 (en) 2004-09-10
ATE430738T1 (de) 2009-05-15
JP2006519194A (ja) 2006-08-24
ECSP055986A (es) 2006-01-16
BRPI0407758A (pt) 2006-02-14
MXPA05008995A (es) 2005-10-18
MXPA05008988A (es) 2005-10-18
AU2004215677B2 (en) 2010-01-07
KR20050106462A (ko) 2005-11-09
DK1599452T3 (da) 2007-10-01
AR043432A1 (es) 2005-07-27
EP1599452A1 (de) 2005-11-30
CO5690578A2 (es) 2006-10-31
US20080167354A1 (en) 2008-07-10
OA13034A (en) 2006-11-10
RU2005129995A (ru) 2006-01-27
US20040209920A1 (en) 2004-10-21
EP1599455B1 (de) 2009-07-01
ES2326418T3 (es) 2009-10-09
EP1599455A1 (de) 2005-11-30
US20080015238A1 (en) 2008-01-17
PL377735A1 (pl) 2006-02-20

Similar Documents

Publication Publication Date Title
NO20054398L (no) 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
WO2007033231A3 (en) Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
NO20081682L (no) 4-oksy-N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20052914L (no) Terapeutiske forbindelser
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
NO20073719L (no) Kjemiske forbindelser
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
NO20083315L (no) 3,5-substituert piperidin-bestanddeler som renin-inhibitorer
MA32455B1 (fr) Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1
NO20072389L (no) Substituerte benzokinolizinderivater
MY160357A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
WO2008043024A3 (en) Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
WO2007134038A3 (en) Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2005097762A3 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
NO20081676L (no) Bicykliske aryl-sulfonylsyre[1,3,4]-tiadlazol-2-yl-amlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
NO20081368L (no) Derivater av 2-amintiazoler og 2-aminooksazoler, fremgangsmate for fremstilling derav samt deres anvendelse som farmasoytika